Randomized trial of pamidronate in patients with thyroid cancer : Bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate

Patients taking suppressive doses of T4 are thought to have accelerated bone loss and increased risk of osteoporosis. We therefore randomize 55 patients taking suppressive doses of T4 to treatment with pamidronate (APD) 30 mg i.v. every 3 months for 2 yr (APD/T4), or placebo (placebo/T4). Patients h...

Ausführliche Beschreibung